These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8509523)
1. Plasma amino acid profiles in relation to clinical response to moclobemide in patients with major depression. Danish University Antidepressant Group. Møller SE J Affect Disord; 1993 Apr; 27(4):225-31. PubMed ID: 8509523 [TBL] [Abstract][Full Text] [Related]
2. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord; 1993 Jun; 28(2):105-16. PubMed ID: 8354766 [TBL] [Abstract][Full Text] [Related]
3. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. Møller SE; Bech P; Bjerrum H; Bøjholm S; Butler B; Folker H; Gram LF; Larsen JK; Lauritzen L; Loldrup D J Affect Disord; 1990 Jan; 18(1):59-66. PubMed ID: 2136870 [TBL] [Abstract][Full Text] [Related]
4. Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain. Civeira J; Cervera S; Giner J; Allen SR; Hellstern K; Malanowski H; Wirz R; Klar K Acta Psychiatr Scand Suppl; 1990; 360():48-9. PubMed ID: 2248070 [TBL] [Abstract][Full Text] [Related]
5. Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Dierick M; Cattiez P; Franck G; Burton P; Defleur J; Hermans W; Roelandts A; Wolfrum C; Berger M; Hellstern K Acta Psychiatr Scand Suppl; 1990; 360():50-1. PubMed ID: 2248071 [TBL] [Abstract][Full Text] [Related]
6. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089 [TBL] [Abstract][Full Text] [Related]
7. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany. Funke HJ; Moritz E; Hellstern K; Malanowski H Acta Psychiatr Scand Suppl; 1990; 360():46-7. PubMed ID: 2248069 [TBL] [Abstract][Full Text] [Related]
8. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574 [TBL] [Abstract][Full Text] [Related]
9. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study. Møller SE; de Beurs P; Timmerman L; Tan BK; Leijnse-Ybema HJ; Stuart MH; Petersen HE Psychopharmacology (Berl); 1986; 88(1):96-100. PubMed ID: 3080781 [TBL] [Abstract][Full Text] [Related]
10. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder. Laux G; Beckmann H; Classen W; Becker T J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Roth M; Guelfi JD Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027 [TBL] [Abstract][Full Text] [Related]
12. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group. Lecrubier Y; Pedarriosse AM; Payan C; Schmid-Burgk W; Stabl M Acta Psychiatr Scand; 1995 Oct; 92(4):260-5. PubMed ID: 8848950 [TBL] [Abstract][Full Text] [Related]
13. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial. Larsen JK; Holm P; Mikkelsen PL Acta Psychiatr Scand; 1984 Sep; 70(3):254-60. PubMed ID: 6388247 [TBL] [Abstract][Full Text] [Related]
14. Determination of 5-hydroxytryptamine and tryptophan by liquid chromatography in whole blood. Its interest for the exploration of mental disorders. Aymard N; Honore P; Carbuccia I Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan; 18(1):77-86. PubMed ID: 8115674 [TBL] [Abstract][Full Text] [Related]
15. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor. Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227 [TBL] [Abstract][Full Text] [Related]
16. Plasma tyrosine/neutral amino acid ratio correlated with clinical response to nortriptyline in endogenously depressed patients. Møller SE; Odum K; Kirk L; Bjerre M; Fog-Møller F; Knudsen A J Affect Disord; 1985 Nov; 9(3):223-9. PubMed ID: 2934455 [TBL] [Abstract][Full Text] [Related]
17. RIMA: a safe concept in the treatment of depression with moclobemide. Amrein R; Hetzel W; Stabl M; Schmid-Burgk W Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030 [TBL] [Abstract][Full Text] [Related]
18. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Fritze J; Laux G; Sofic E; Koronakis P; Schoerlin MP; Riederer P; Beckmann H Psychopharmacology (Berl); 1989; 99(2):252-6. PubMed ID: 2508163 [TBL] [Abstract][Full Text] [Related]
19. An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression. Evans L; George T; O'Sullivan B; Mitchell P; Johnson G; Adena M Aust N Z J Psychiatry; 1992 Sep; 26(3):454-8. PubMed ID: 1417632 [TBL] [Abstract][Full Text] [Related]
20. Thyroid functioning during treatment for depression. Kusalic M; Engelsmann F; Bradwejn J J Psychiatry Neurosci; 1993 Nov; 18(5):260-3. PubMed ID: 8297924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]